Gene-based therapies for neuromuscular disorders

Neuromuscular diseases (NMD) include a broad group of medical conditions with both acquired and genetic causes. In recent years, important advances have been made in the treatment of genetically caused NMD, and most of these advances are due to the implementation of therapies aimed at gene regulatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Edmar Zanoteli, Marcondes Cavalcante França, Wilson Marques
Format: Article
Language:English
Published: Thieme Revinter Publicações 2024-06-01
Series:Arquivos de Neuro-Psiquiatria
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1777755
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuromuscular diseases (NMD) include a broad group of medical conditions with both acquired and genetic causes. In recent years, important advances have been made in the treatment of genetically caused NMD, and most of these advances are due to the implementation of therapies aimed at gene regulation. Among these therapies, gene replacement, small interfering RNA (siRNA), and antisense antinucleotides are the most promising approaches. More importantly, some of these therapies have already gained regulatory approval or are in the final stages of approval. The review focuses on motor neuron diseases, neuropathies, and Duchenne muscular dystrophy, summarizing the most recent developments in gene-based therapies for these conditions.
ISSN:0004-282X
1678-4227